Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Ben Sutter could only eat three things after being diagnosed with eosinophilic gastroenteritis as a baby. A medical ...

Dupixent is the first and only medication for these young patients, with approvals also in place in Canada and the US. The EMA's decision is based on the outcomes of EoE KIDS, a two-part ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old . ... EoE KIDS phase 3 study in children aged one to 11 years.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old Sep. 20, 2024 7:45 AM ET Sanofi (SNY) , REGN ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

TORONTO, Sept. 12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...